Top Back to top

Use of eculizumab to treat thrombotic microangiopathy associated with haematopoietic stem cell transplantation - a retrospective study on behalf of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation

Study number:
 
Type of transplant:
 
Diseases:
 
Short title:
 
Study status:
 
Deadline for data collection:
 
Study design:
 
Primary objective:
Primary objective is to determine the effectivity of eculizumab treatment in HSCT-TMA in children.The goal is to collect the unpublished real-life experience of eculizumab use that may help the current practice and shape the future research.
Key inclusion criteria:
- Age 0-18yrs
- Allogeneic haematopoietic stem cell transplantation recipient
- HSCT-TMA diagnosed according to any of the 6 criteria listed (defined in the questionnaire, attached))
- Treatment with eculizumab
- Informed consent given for EBMT registry data collection
Country:
 
Principal investigator:
Peter Svec
Principal investigator email:
 
EBMT Study coordinator:
Arnaud Dalissier